Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Protocol Version 7/30/2024 | Other Identifier | UW Madison | |
| SMPH/RADIOLOGY/RADIOLOGY | Other Identifier | UW Madison | |
| UW23020 | Other Identifier | UWCCC OnCore ID | |
| 1R01CA272571-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The overall purpose of this research is to test the efficacy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy and to determine the quantitative reliability of 18F-FFNP breast PET/MRI in patients with newly diagnosed PR+ primary breast cancer.
Primary Objective
• Determine the diagnostic accuracy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy.
Secondary Objectives
Exploratory Objectives
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1: Metabolite Analysis | Experimental | participants will undergo venous blood sampling during the PET/MRI scan |
|
| Group 2: Pre-surgical Treatment | Experimental | participants will undergo PET/MRI scans before and after 2 weeks treatment with anastrozole |
|
| Group 3: Test-Retest | Experimental | participants will undergo baseline and repeat PET/MRI scans without intervening treatment to determine repeatability |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 18F-fluorofuranylnorprogesterone | Drug | 18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage change in 18F-FFNP uptake between baseline and follow-up PET/MRI scans | Tumor uptake values of 18F-FFNP will be obtained from the attenuation corrected PET component of the simultaneous breast 18F-FFNP PET/MRI research scan according to the procedures detailed in the imaging manual and the FDA IND. | up to 4 weeks on study and up to 7 weeks on study |
| Percentage change in tumor Ki67 proliferation score, as a surrogate measure of endocrine sensitivity | Baseline Ki67 proliferation immunohistochemistry score will be obtained from the existing clinical standard-of-care breast biopsy. Post-treatment K67 proliferation immunohistochemistry score will be obtained from the surgical specimen after excision. Treatment response is defined as a reduction in Ki67 score of greater than or equal to 60 percent. Treatment nonresponse is defined as a reduction of less than 60 percent. | up to 4 weeks on study and up to 7 weeks on study |
| Measure | Description | Time Frame |
|---|---|---|
| Qualitative Analysis of 18F-FFNP uptake | 18F-FFNP uptake will be visually evaluated qualitatively with the following grading scale: no uptake (tumor < background), minimal uptake (tumor = background), mild (tumor slightly > background), moderate uptake (tumor >> background), and intense uptake (tumor >>> background). Tumor uptake will also be dichotomized as increased (mild, moderate, or intense uptake) or absent (no uptake, minimal). |
| Measure | Description | Time Frame |
|---|---|---|
| Summary of Parent and Metabolite Fractions of 18F-FFNP over the course of the scan | Median and interquartile ranges will be calculated for metabolized and unmetabolized (parent) 18F-FFNP obtained from subjects undergoing venous blood sampling in the metabolite study and plotted against time. | imaging takes up to 2 hours during a visit and will take place up to 4 weeks on study for Group 1 |
Inclusion Criteria:
Postmenopausal status defined by either
Diagnosis of biopsy-proven invasive breast cancer measuring at least 1.0 cm in diameter by any imaging modality. Malignancy may be located within the breast, axilla (e.g. metastatic axillary lymph node), or both the breast and axilla
Biopsy-proven PR-positive invasive breast cancer
Definitive surgical excision of the primary tumor planned without neoadjuvant therapy; defined as therapy (chemotherapy, targeted therapy, radiation therapy or endocrine therapy) given to decrease the size of the tumor prior to planned surgery. (Group 2 only)
Exclusion Criteria:
Inability or unwillingness to provide informed consent to the study
HER2-positive breast cancer, as defined by immunohistochemical staining 3+ OR positive by in situ hybridization (Group 2 only)
PR and Ki67 IHC slides or FFPE tissue blocks from clinical breast biopsy not available
Patients who have completed neoadjuvant chemotherapy, endocrine therapy, targeted therapy, surgical resection, or radiation for the current biopsy-proven malignancy (Group 2 only)
Patients who are planning to undergo anastrozole as standard of care neoadjuvant therapy
Patients who are currently taking aromatase inhibitors or ER antagonists (tamoxifen, raloxifene)
Patients with breast expanders
Patients who are pregnant or lactating
Patients with clinical contraindication for use of aromatase inhibitors (AI) while on study as determined by investigator (Group 2 only)
Patients with a contraindication to gadolinium-based contrast agents, including allergy or impaired renal function (per UW Health Guidelines)
Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FFNP
Patients with history of allergic reaction to anastrozole (Group 2 only)
Patients in liver failure as judged by the patient's physician
Patients with standard contraindications to MRI (per UW Health Guidelines)
Patients requiring conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the clinical MRI scan will be allowed to participate as long as the following criteria are met:
Patients unable to lie prone for 45 minutes for imaging
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Cancer Connect | Contact | 800-622-8922 | clinicaltrials@cancer.wisc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Amy M Fowler, MD, PHD | UW Carbone Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UW Carbone Cancer Center | Recruiting | Madison | Wisconsin | 53792 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008279 | Magnetic Resonance Imaging |
| D000077384 | Anastrozole |
| D001800 | Blood Specimen Collection |
| C000656634 | gadopiclenol |
| ID | Term |
|---|---|
| D014054 | Tomography |
| D003952 | Diagnostic Imaging |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Window of Opportunity
Not provided
Not provided
Not provided
Not provided
|
| Positron Emissions Tomography / Magnetic Resonance Imaging | Device | Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare) |
|
|
| Anastrozole | Drug | hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days |
|
| Blood Sampling | Other | Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions |
|
| FDA-approved gadolinium-based intravenous contrast agent | Drug | FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study |
|
|
| imaging takes up to 2 hours during a visit and will take place up to 4 weeks and up to 6 weeks for the test-retest Group 3 |
| Intra- and Inter-Observer Variability of Quantitative Assessment of Tumor 18F-FFNP uptake | For the test-retest portion of the clinical trial, the mixed effects model framework will be utilized to determine the intra- and interobserver variability of quantitative assessment of tumor 18F-FFNP uptake via a parametric bootstrapping approach. | imaging takes up to 2 hours during a visit and will take place up to 4 weeks and up to 6 weeks for the test-retest Group 3 |
| Quantitative Assessment of Tumor 18F-FFNP: Standardized Uptake Values (SUV) | Differences in repeatability of the different SUV measures (SUVmax, SUVpeak, and SUVmean) and their respective methods of normalization will be assessed by comparing the variances of the relative test-retest differences, using the Pitnam-Morgan test for correlated variances. | imaging takes up to 2 hours during a visit and will take place up to 4 weeks and up to 6 weeks for the test-retest Group 3 |
| Test-Retest Variability of Quantitative Assessment of Tumor 18F-FFNP uptake | For the test-retest portion of the clinical trial, the mixed effects model framework will be utilized to determine the test-retest variability of quantitative assessment of tumor 18F-FFNP uptake via a parametric bootstrapping approach. | imaging takes up to 2 hours during a visit and will take place up to 4 weeks and up to 6 weeks for the test-retest Group 3 |
| NCIC Adverse Events Version 5.0 Frequency Tables | Safety and tolerability of 18F-FFNP by NCIC Adverse Events Version 5.0 will be assessed by frequency tables and possible relationship to study drug as assessed by the investigators. | up to 7 weeks |
| Statistical Correlation between tumor 18F-FFNP uptake with serum progesterone, 17-OH progesterone, estradiol, and corticosteroid binding globulin levels | Pearson's or Rank correlation analysis will be performed to assess the association between tumor 18F-FFNP uptake with serum progesterone, estradiol, and corticosteroid binding globulin levels. Scatter plots, correlation coefficients (rho), 95% confidence intervals, and p values will be reported. | imaging takes up to 2 hours during a visit and will take place up to 4 weeks on study for Group 1 |
| Statistical correlation between 18F-FFNP breast PET/MRI parameters and changes in PR immunohistochemistry in therapy responders and non-responders | An ANCOVA model, which will include treatment as a fixed effect and the corresponding baseline value as a covariate, and a paired t-test will be utilized to compare the change in tumor 18F-FFNP update after window treatment with change in PR immunostaining from the biopsy to surgical specimen. Means and standard errors will be presented. Least-squares means and 95% CI will be reported. Furthermore, correlation analyses will be performed to describe these associations. | imaging takes up to 2 hours during a visit and will take place up to 4 weeks on study for Group 1, up to 4 weeks and up to 7 weeks for Group 2, and up to 4 weeks and up to 6 weeks for Group 3 |
| Statistical correlation between tumor 18F-FFNP uptake with disease recurrence | If there is sufficient follow-up data for disease recurrence, the Kaplan-Meier method will be used to analyze time to disease recurrence, defined as date of imaging day until disease recurrence. Patients who do not experience disease recurrence will be censored at the date of last available follow-up. A Cox proportional hazards model will be used to evaluate the association of tumor 18F-FFNP uptake with time to disease recurrence. If there is insufficient follow-up data, descriptive statistics will be used to summarize tumor 18F-FFNP uptake for those patients with disease recurrence | up to 5 years (long term follow up) |
| Statistical determination of whether MRI parameters improve the predictive value of FFNP PET alone | The investigators will explore whether adding MRI parameters improves the AUC of 18F-FFNP PET alone. Regression models will be performed on the following parameters: quantitative tumor perfusion (signal enhancement ratio, functional tumor volume), quantitative tumor diffusion (apparent diffusion coefficient), qualitative morphologic phenotype (categories I, II, III, IV), and qualitative background parenchymal enhancement (categories are minimal, mild, moderate, marked). | up to 5 years (long term follow up) |
| D017437 |
| Skin and Connective Tissue Diseases |
| D009570 |
| Nitriles |
| D009930 | Organic Chemicals |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |